Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling

Laboratory Investigation

Volumn 94, Issue 5, 2014, Pages 503-516

  Tang, Youcai ^a   Chen, Anping ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

advanced glycation end products; glutathione; hepatic fibrosis; hepatic stellate cells; oxidant stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA ACTIN; CURCUMIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; JANUS KINASE 2; LEPTIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REDUCTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHROMONES; CURCUMA; CURCUMIN; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPATIC STELLATE CELLS; LEPTIN; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LEPTIN; TYRPHOSTINS;

EID: 84899571370     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.42     Document Type: Article

References (72)

1. Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-248.
2. Ribeireiro T, Swain J, Sarr M, et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery-a prospective analysis. Obes Surg 2011;21:310-315.
3. Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:G825-G834.
4. Stefanovic A, Kotur-Stevuljevic J, Spasic S, et al. The influence of obesity on the oxidative stress status and the concentration of leptin in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2008;79:156-163.
5. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-886.
6. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
7. Smedsrod B, Melkko J, Araki N, et al. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997; 322(Pt 2):567-573.
8. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-1119.
9. Schmidt AM, Yan SD, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111.
10. Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012;57:160-167.
11. Lu C, He JC, Cai W, et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 2004;101:11767-11772.
12. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-1712.
13. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
14. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996;93:11047-11052.
15. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004;10:563-569.
16. Yokaichiya DK, Galembeck E, Torres BB, et al. Insulin and leptin relations in obesity: a multimedia approach. Adv Physiol Educ 2008; 32:231-236.
17. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632-635.
18. Leclercq IA, Farrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37: 206-213.
19. Sakaida I, Jinhua S, Uchida K, et al. Leptin receptor-deficient Zucker (fa/fa) rat retards the development of pig serum-induced liver fibrosis with Kupffer cell dysfunction. Life Sci 2003;73:2491-2501.
20. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
21. Saxena NK, Ikeda K, Rockey DC, et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-771.
22. Saxena NK, Saliba G, Floyd JJ, et al. Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 2003;89:311-320.
23. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005;42:1339-1348.
24. Tang Y, Zheng S, Chen A. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009;150:3011-3020.
25. Wells RG. Liver fibrosis: challenges of the new era. Gastroenterology 2009;136:387-388.
26. Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11: 1231-1249.
27. Federico A, Niosi M, Vecchio Blanco CD, et al. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs 2008;13: 145-158.
28. O'Connell MA, Rushworth SA. Curcumin: potential for hepatic fibrosis therapy? Br J Pharmacol 2008;153:403-405.
29. Aggarwal BB, Sundaram C, Malani N, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75.
30. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003;285:G20-G30.
31. Zheng S, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004; 384(Pt 1):149-157.
32. Zheng S, Chen A. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol Gastrointest Liver Physiol 2006;290:G883-G893.
33. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-G123.
34. Zheng S, Yumei F, Chen A. De novo synthesis of glutathione is a prerequisite for curcumin to inhibit hepatic stellate cell (HSC) activation. Free Radic Biol Med 2007;43:444-453.
35. Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
36. Nanji AA, Jokelainen K, Tipoe GL, et al. Curcumin prevents alcoholinduced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 2003;284:G321-G327.
37. Park EJ, Jeon CH, Ko G, et al. Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J Pharm Pharmacol 2000;52: 437-440.
38. Lin J, Tang Y, Kang Q, et al. Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest 2012;92: 827-841.
39. Lin J, Tang Y, Kang Q, et al. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARgamma activity and attenuating oxidative stress. Br J Pharmacol 2012;166:2212-2227.
40. Schmittgen TD, Zakrajsek BA, Mills AG, et al. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000;285:194-204.
41. Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res 2006;66:10983-10994.
42. So HS, Kim HJ, Lee JH, et al. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ 2006;13:1763-1775.
43. Mohr A, Fahrenkamp D, Rinis N, et al. Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain. Cell Commun Signal 2013;11:83.
44. Tang Y, Chen A. Curcumin protects hepatic stellate cells against leptininduced activation in vitro by accumulating intracellular lipids. Endocrinology 2010;151:4168-4177.
45. Tang Y, Chen A. Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol 2010;161:1137-1149.
46. Sterenczak KA, Nolte I, Murua Escobar H. RAGE splicing variants in mammals. Methods Mol Biol 2013;963:265-276.
47. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004;81:223-241.
48. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006;393(Pt 1):7-20.
49. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86.
50. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005;7:385-394.
51. Fraser JA, Kansagra P, Kotecki C, et al. The modifier subunit of Drosophila glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo. J Biol Chem 2003;278:46369-46377.
52. Fridovich I. The biology of oxygen radicals. Science 1978;201:875-880.
53. Jones DP. Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 2002;348:93-112.
54. Seelig GF, Simondsen RP, Meister A. Reversible dissociation of gammaglutamylcysteine synthetase into two subunits. J Biol Chem 1984;259: 9345-9347.
55. Sekura R, Meister A. gamma-Glutamylcysteine synthetase. Further purification, "half of the sites" reactivity, subunits, and specificity. J Biol Chem 1977;252:2599-2605.
56. Mulcahy RT, Wartman MA, Bailey HH, et al. Constitutive and betanaphthoflavone-induced expression of the human gammaglutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence. J Biol Chem 1997;272:7445-7454.
57. Moinova HR, Mulcahy RT. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gammaglutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem 1998;273: 14683-14689.
58. Guan SP, Tee W, Ng DS, et al. Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br J Pharmacol 2013;168:1707-1718.
59. Sebekova K, Kupcova V, Schinzel R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatol 2002; 36:66-71.
60. Makita Z, Vlassara H, Cerami A, et al. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267: 5133-5138.
61. Vlassara H, Uribarri J, Cai W, et al. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann NY Acad Sci 2008;1126:46-52.
62. Vlassara H. Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101.
63. Lohwasser C, Neureiter D, Popov Y, et al. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol 2009;15:5789-5798.
64. Ekong U, Zeng S, Dun H, et al. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006;21:682-688.
65. Yamagishi S, Nakamura K, Matsui T, et al. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008;17:983-996.
66. Fei H, Okano HJ, Li C, et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 1997;94:7001-7005.
67. Bernotiene E, Palmer G, Gabay C. The role of leptin in innate and adaptive immune responses. Arthritis Res Ther 2006;8:217.
68. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006;21(Suppl 3):S84-S87.
69. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010;3: 101-108.
70. Bryan HK, Olayanju A, Goldring CE, et al. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol 2013;85:705-717.
71. Folch J, Pedros I, Patraca I, et al. Neuroprotective and anti-ageing role of leptin. J Mol Endocrinol 2012;49:R149-R156.
72. Liu XM, Peyton KJ, Shebib AR, et al. Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am J Physiol Heart Circ Physiol 2011;300:H84-H93.